Trial reportJAMA network open2026
Time of Detection of Liver Metastases and Survival in Patients With Colorectal Cancer.
Trial report in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Colorectal cancer liver metastases (CRLM) are a common manifestation of colorectal cancer, and clinical decision-making for these patients is complex. The timing of CRLM detection, defined as synchronous, early metachronous, or late metachronous, is hypothesized to influence survival outcomes, but the prognostic implications of these classifications remain unclear. Objective: To determine whether the timing of CRLM detection is associated with overall survival (OS) in patients with up-front locally treatable or initially nonlocally treatable CRLM. Design, Setting, and Participants: Multicenter cohort study including adult patients from the Amsterdam Colorectal Liver Met Registry and the phase 3 CAIRO5 trial between 2000 and 2024, with analyses conducted from March 2025 to January 2026. Patients were followed up for a median (IQR) of 44 (41-48) months. Survival outcomes were analyzed using multivariable Cox regression models. Inclusion criteria were up-front locally treatable or initially nonlocally treatable CRLM, with key clinical and demographic characteristics recorded. Exposure: Timing of CRLM detection categorized as synchronous (detected before or at primary CRC diagnosis or during surgery), early metachronous (within 12 months of diagnosis or surgery), or late metachronous (more than 12 months after surgery), according to European-African Hepato-Pancreato-Biliary Association consensus guidelines. Main Outcomes and Measures: OS from diagnosis of CRLM, stratified by CRLM timing and treatment received. Multivariable analysis accounted for tumor number, size, variant status, carcinoembryonic antigen levels, and treatment strategy. Results: A total of 1250 patients were included (median [IQR] age, 63 [56-72] years; 823 [65.9%] men), of whom 817 (65%) had synchronous CRLM, 208 (17%) early metachronous CRLM, and 225 (18%) late metachronous CRLM. Among all patients, 676 (54%) died during follow-up. Synchronous CRLM were associated with worse OS compared with early metachronous CRLM (hazard ratio [HR], 0.79; 95% CI, 0.64-0.97) and late metachronous CRLM (HR, 0.54; 95% CI, 0.43-0.68). After adjustment for tumor and treatment factors, timing of detection of CRLM was not independently associated with OS. Conclusions and Relevance: In this retrospective multicenter cohort study, timing of CRLM detection was not associated with OS when accounting for tumor characteristics and treatment strategy. These findings suggest that synchronicity may primarily reflect underlying tumor biology rather than directly influencing survival, emphasizing that clinical decisions should focus on synchronicity in combination with tumor burden, variant status, and local treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.